Geli\u015fmekte olan b\u00f6lgelerdeki kanser tarama protokollerini k\u00f6kten de\u011fi\u015ftirebilecek b\u00fcy\u00fck \u00f6l\u00e7ekli ve kapsaml\u0131 bir ara\u015ft\u0131rma olan CHinA National CancEr Screening (CHANCES) \u00e7al\u0131\u015fmas\u0131 ba\u015flad\u0131. Bu be\u015f y\u0131l s\u00fcrecek randomize kontroll\u00fc \u00e7al\u0131\u015fma, akci\u011fer ve kolorektal kanser tarama y\u00f6ntemlerini optimize etmeyi ama\u00e7layarak, erken te\u015fhisi g\u00fc\u00e7lendirecek ve geli\u015fmekte olan \u00fclkelerde hala y\u00fcksek seyreden kanser kaynakl\u0131 \u00f6l\u00fcmleri azaltmay\u0131 hedefliyor. Ara\u015ft\u0131rma, \u00c7in\u2019in 25 eyaletinden 50-74 ya\u015f aral\u0131\u011f\u0131nda 105.600 kat\u0131l\u0131mc\u0131n\u0131n dahil edildi\u011fi unprecedented bir b\u00fcy\u00fckl\u00fckte y\u00fcr\u00fct\u00fcl\u00fcyor. B\u00f6ylece, n\u00fcfus temelli verilerin s\u0131n\u0131rl\u0131 oldu\u011fu geli\u015fmekte olan \u00fclkelerde y\u00fcksek kalitede kan\u0131tlar sa\u011flanmas\u0131 ama\u00e7lan\u0131yor.<\/p>\n
CHANCES \u00e7al\u0131\u015fmas\u0131n\u0131n ortaya \u00e7\u0131k\u0131\u015f sebebi, \u00f6zellikle d\u00fc\u015f\u00fck ve orta gelirli \u00fclkelerde kanser tan\u0131 oranlar\u0131n\u0131n zengin \u00fclkelere k\u0131yasla geride kalmas\u0131d\u0131r. Bu durumun \u00fcstesinden gelmek i\u00e7in geni\u015f \u00e7apl\u0131 ve kapsaml\u0131 bir tarama protokol\u00fcn\u00fcn bilimsel temellerle de\u011ferlendirilmesi gerekmektedir. \u00c7al\u0131\u015fma, \u00c7in\u2019in farkl\u0131 b\u00f6lgelerinden kat\u0131l\u0131mc\u0131lar\u0131n al\u0131nmas\u0131 sayesinde, k\u00fclt\u00fcrel ve ekonomik farkl\u0131l\u0131klar\u0131n tarama sonu\u00e7lar\u0131na etkisini detayl\u0131 bi\u00e7imde inceleyebilecek. Bu sayede ulusal ve uluslararas\u0131 kanser tarama stratejileri i\u00e7in hem hasta uyumu hem de maliyet etkinli\u011fi a\u00e7\u0131s\u0131ndan \u00f6nemli veriler ortaya konacak.<\/p>\n
Ara\u015ft\u0131rman\u0131n merkezinde, \u00f6zellikle akci\u011fer kanseri taramas\u0131 i\u00e7in d\u00fc\u015f\u00fck dozlu bilgisayarl\u0131 tomografi (LDCT) yer almakta. LDCT, akci\u011fer i\u00e7indeki nod\u00fclleri \u00e7ok daha erken d\u00f6nemde saptayabilen yeni nesil bir teknoloji olmas\u0131 nedeniyle kritik \u00f6neme sahip. \u00c7al\u0131\u015fma, y\u0131ll\u0131k ile iki y\u0131lda bir yap\u0131lan LDCT taramalar\u0131n\u0131n akci\u011fer kanserine ba\u011fl\u0131 \u00f6l\u00fcm oranlar\u0131 \u00fczerindeki etkilerini kar\u015f\u0131la\u015ft\u0131r\u0131yor. Bat\u0131 \u00fclkelerinde yap\u0131lm\u0131\u015f baz\u0131 \u00e7al\u0131\u015fmalar bu y\u00f6ntemin faydalar\u0131n\u0131 g\u00f6stermi\u015f olsa da, \u00c7in gibi geni\u015f ve heterojen toplumlarda yeterli veri bulunmamaktad\u0131r. CHANCES bu bo\u015flu\u011fu dolduracak.<\/p>\n
Ayn\u0131 zamanda kolorektal kanser (KRK) taramas\u0131 da \u00e7al\u0131\u015fma kapsam\u0131nda de\u011ferlendirilmektedir. KRK, d\u00fcnya \u00e7ap\u0131nda kanserden \u00f6l\u00fcmlerde ba\u015fta gelen nedenlerden biridir ve tarama ile erken a\u015famada tespit edilmesi y\u00fcksek oranda ba\u015far\u0131l\u0131d\u0131r. CHANCES, kolonoskopia ve fekal imm\u00fcnokimyasal test (FIT) gibi farkl\u0131 tarama y\u00f6ntemlerinin kar\u015f\u0131la\u015ft\u0131rmas\u0131n\u0131 yaparak, \u00c7in sa\u011fl\u0131k sistemi i\u00e7inde bunlar\u0131n uygulanabilirlik ve etkinliklerini belirlemeyi ama\u00e7l\u0131yor. FIT pozitif \u00e7\u0131kanlar\u0131n kolonoskopiye y\u00f6nlendirilmesi, hem duyarl\u0131l\u0131\u011f\u0131 art\u0131ran hem de hasta uyumunu kolayla\u015ft\u0131ran pratik bir yakla\u015f\u0131m olarak planland\u0131.<\/p>\n
Ara\u015ft\u0131rmaya kat\u0131lanlar \u00fc\u00e7 ayr\u0131 gruba randomize edildi. Birinci grupta be\u015f ard\u0131\u015f\u0131k y\u0131ll\u0131k LDCT taramas\u0131 ve 1 defa kolonoskopi yap\u0131lacak, bu sayede hem akci\u011fer hem de kolon kanseri i\u00e7in maksimum erken te\u015fhis hedefleniyor. \u0130kinci grupta ise \u00fc\u00e7 kez iki y\u0131ll\u0131k LDCT ve be\u015f \u0131\u015f y\u0131ll\u0131k FIT testi uygulanacak. Bu grup, g\u00f6r\u00fcnt\u00fcleme ile biyokimyasal testin birlikte kullan\u0131m\u0131n\u0131n duyarl\u0131l\u0131\u011f\u0131 art\u0131r\u0131rken invaziv i\u015flemleri azalt\u0131p azaltmad\u0131\u011f\u0131n\u0131 g\u00f6sterecek. \u00dc\u00e7\u00fcnc\u00fc grup ise bir kez kolonoskopi veya be\u015f y\u0131l boyunca y\u0131ll\u0131k FIT testlerinden birini se\u00e7erek daha geleneksel y\u00f6ntemleri kar\u015f\u0131la\u015ft\u0131rma a\u00e7\u0131s\u0131ndan kontrol grubu g\u00f6revini g\u00f6recek.<\/p>\n
\u00c7al\u0131\u015fman\u0131n b\u00fcy\u00fckl\u00fc\u011f\u00fc ve kullan\u0131lan karma\u015f\u0131k tarama protokolleri onu benzersiz k\u0131l\u0131yor. T\u00fcm kat\u0131l\u0131mc\u0131lar\u0131n takibi be\u015f y\u0131l boyunca detayl\u0131 olarak yap\u0131larak, yaln\u0131zca kanser g\u00f6r\u00fclme s\u0131kl\u0131\u011f\u0131 de\u011fil, ayn\u0131 zamanda mortalite ve ya\u015fam kalitesi gibi uzun d\u00f6nem etkiler de kay\u0131t alt\u0131na al\u0131nacak. Harcamalar\u0131n analiz edilmesi de programlar\u0131n s\u00fcrd\u00fcr\u00fclebilirli\u011fi a\u00e7\u0131s\u0131ndan \u00f6nemli veriler sa\u011flayacak. B\u00f6ylece, s\u0131n\u0131rl\u0131 kaynaklara sahip \u00fclkeler i\u00e7in ekonomik y\u00f6nden uygun tarama stratejilerinin belirlenmesi m\u00fcmk\u00fcn olabilecek.<\/p>\n
CHANCES \u00e7al\u0131\u015fmas\u0131, \u00f6zellikle Asyal\u0131 n\u00fcfusta LDCT\u2019nin y\u0131ll\u0131k veya iki y\u0131ll\u0131k kullan\u0131m\u0131n\u0131n akci\u011fer kanserine ba\u011fl\u0131 \u00f6l\u00fcm oranlar\u0131n\u0131 azaltma potansiyeli a\u00e7\u0131s\u0131ndan sistematik olarak incelenen ilk b\u00fcy\u00fck randomize kontroll\u00fc \u00e7al\u0131\u015fmad\u0131r. Bu \u00f6nemli, \u00e7\u00fcnk\u00fc akci\u011fer kanseri risk fakt\u00f6rleri ve sa\u011fl\u0131k kaynaklar\u0131n\u0131n da\u011f\u0131l\u0131m\u0131 b\u00f6lgeden b\u00f6lgeye de\u011fi\u015fiklik g\u00f6sterdi\u011fi i\u00e7in, bat\u0131 \u00fclkelerinden elde edilen verilerin do\u011frudan kullan\u0131lmas\u0131 m\u00fcmk\u00fcn olmayabilir. \u00c7in gibi b\u00fcy\u00fck bir \u00fclkede edinilen kan\u0131tlar, b\u00f6lgesel ve global sa\u011fl\u0131k politikalar\u0131nda yol g\u00f6sterici olacakt\u0131r.<\/p>\n
Taraman\u0131n akci\u011fer ve kolorektal kanser programlar\u0131n\u0131n bir arada y\u00fcr\u00fct\u00fcld\u00fc\u011f\u00fc inovatif model, kaynaklar\u0131n verimli kullan\u0131m\u0131n\u0131 ve hasta kat\u0131l\u0131m\u0131n\u0131 art\u0131rmay\u0131 hedefliyor. Bu \u00e7ift hedefli yakla\u015f\u0131m, y\u00fcksek kanser y\u00fck\u00fc ile m\u00fccadele eden ba\u015fka \u00fclkeler i\u00e7in de model te\u015fkil edebilir. \u00d6zellikle kaynak k\u0131s\u0131tl\u0131 alanlarda entegre tarama programlar\u0131n\u0131n daha etkin uygulanmas\u0131na olanak sa\u011flayabilir.<\/p>\n
Ara\u015ft\u0131rma ekibi, kat\u0131l\u0131mc\u0131 uyumunu sa\u011flamak i\u00e7in \u00f6zellikle yo\u011fun \u00e7aba sarf ediyor. Karma\u015f\u0131k tarama protokolleri nedeniyle d\u00fczenli kontrol ve hasta e\u011fitim programlar\u0131 geli\u015ftirildi. Buna ek olarak toplum baz\u0131nda bilgilendirme ve fark\u0131ndal\u0131k art\u0131rma \u00e7al\u0131\u015fmalar\u0131na yer veriliyor. Bu sayede bilimsel titizlik ile ger\u00e7ek d\u00fcnya uygulamalar\u0131n\u0131n dengesi g\u00f6zetiliyor ve uygulamaya y\u00f6nelik engeller en aza indirgeniyor.<\/p>\n
CHANCES, \u00c7in Klinik Ara\u015ft\u0131rma Kayd\u0131\u2019na (ChiCTR1900025257) kay\u0131tl\u0131 olup; \u015feffaf ve uluslararas\u0131 standartlarda yap\u0131lan bir \u00e7al\u0131\u015fma olmas\u0131yla da g\u00fcvenilirli\u011fini art\u0131rmaktad\u0131r. A\u00e7\u0131k veri payla\u015f\u0131m\u0131 ve i\u015f birli\u011fi ortam\u0131 yarat\u0131lmas\u0131, hem \u00c7in i\u00e7inde hem de geli\u015fmekte olan \u00fclkelerde benzer projelerin ortaya \u00e7\u0131kmas\u0131n\u0131 te\u015fvik edecektir. B\u00f6ylelikle, d\u00fcnya genelinde kanser tarama politikalar\u0131n\u0131n geli\u015ftirilmesinde \u00f6nemli rol oynayacakt\u0131r.<\/p>\n
Sonu\u00e7lar\u0131 ba\u015far\u0131l\u0131 olursa, CHANCES \u00e7al\u0131\u015fmas\u0131n\u0131n hem akci\u011fer kanseri i\u00e7in tarama aral\u0131\u011f\u0131n\u0131n yeniden de\u011ferlendirilmesini hem de g\u00f6r\u00fcnt\u00fcleme ve biyolojik testlerin entegre edilmesini sa\u011flayan stratejilerin geli\u015ftirilmesini sa\u011flamas\u0131 bekleniyor. Bu da d\u00fcnya genelinde artan kanser vakalar\u0131 ve s\u0131n\u0131rl\u0131 sa\u011fl\u0131k b\u00fct\u00e7eleri kar\u015f\u0131s\u0131nda \u00f6nemli bir f\u0131rsat olarak de\u011ferlendirilebilir. Kaynaklar\u0131n etkin kullan\u0131m\u0131, erken te\u015fhisin yayg\u0131nla\u015fmas\u0131 ve tedavi maliyetlerinin d\u00fc\u015f\u00fcr\u00fclmesi ad\u0131na b\u00fcy\u00fck bir potansiyel ta\u015f\u0131maktad\u0131r.<\/p>\n
Erken kanser te\u015fhisindeki geli\u015fmeler, milyonlarca hayat\u0131n kurtar\u0131lmas\u0131 ve ileri evre tedavi maliyetlerinin minimize edilmesi a\u00e7\u0131s\u0131ndan son derece \u00f6nemlidir. CHANCES \u00e7al\u0131\u015fmas\u0131n\u0131n klinik etkinlik ve maliyet etkinli\u011fi yan\u0131nda, sa\u011fl\u0131k sistemi i\u00e7inde pratik uygulamas\u0131n\u0131 da g\u00f6z \u00f6n\u00fcne alarak sundu\u011fu kapsaml\u0131 de\u011ferlendirme, ara\u015ft\u0131rman\u0131n ulusal ve uluslararas\u0131 d\u00fczeyde etkisini art\u0131racakt\u0131r. Sa\u011fl\u0131k politikalar\u0131n\u0131 belirleyenler, \u00e7al\u0131\u015fman\u0131n sonu\u00e7lar\u0131n\u0131 yak\u0131ndan takip etmektedirler.<\/p>\n
Ara\u015ft\u0131rma \u00f6zellikle sa\u011fl\u0131k politikac\u0131lar\u0131, klinik hekimler ve hasta savunucular\u0131 i\u00e7in b\u00fcy\u00fck umut vaat etmektedir. Geli\u015fmekte olan b\u00f6lgelere \u00f6zg\u00fc kanser tarama \u00f6nerileri sunmas\u0131, halk sa\u011fl\u0131\u011f\u0131 yakla\u015f\u0131m\u0131nda \u00f6nemli bir d\u00f6n\u00fcm noktas\u0131 olabilir. Ayn\u0131 zamanda, taramaya olan toplumsal fark\u0131ndal\u0131\u011f\u0131n artmas\u0131, insanlar\u0131n erken sa\u011fl\u0131k hizmeti arama al\u0131\u015fkanl\u0131klar\u0131n\u0131n geli\u015fmesi y\u00f6n\u00fcnde olumlu bir etki yaratacakt\u0131r.<\/p>\n
Kanser kontrol\u00fc alan\u0131ndaki bu bilimsel geli\u015fme, teknolojik yeniliklerin ve taraman\u0131n k\u00fcresel \u00f6ncelik haline gelmesinin tam ortas\u0131nda ger\u00e7ekle\u015fiyor. Ancak, uygulanabilir ve b\u00f6lgeye \u00f6zg\u00fc verilerin azl\u0131\u011f\u0131 bu alandaki \u00e7abalar\u0131 s\u0131n\u0131rlamaktayd\u0131. CHANCES \u00e7al\u0131\u015fmas\u0131, bu bo\u015flu\u011fu doldurarak umut verici bir \u00f6rnek olu\u015fturuyor ve geli\u015fmekte olan \u00fclkelerde benzer \u00e7al\u0131\u015fmalar\u0131n \u00f6n\u00fcn\u00fc a\u00e7\u0131yor.<\/p>\n
Lojistik zorluklar ve b\u00f6lgesel e\u015fitsizlikler gibi engeller elbette ki var, ancak ara\u015ft\u0131rma ekibi \u00c7in\u2019in geni\u015f sa\u011fl\u0131k altyap\u0131s\u0131n\u0131 ve yenilik\u00e7i yakla\u015f\u0131m\u0131n\u0131 haiz olarak bunlar\u0131n \u00fcstesinden gelmeyi planl\u0131yor. Multidisipliner bir ekip \u00e7al\u0131\u015fmas\u0131yla, hem sahadaki uygulamalar\u0131n takibi hem de bilimsel verilerin do\u011frulu\u011fu b\u00fcy\u00fck \u00f6zenle sa\u011flan\u0131yor. B\u00f6ylece \u00e7al\u0131\u015fma, karma\u015f\u0131k sa\u011fl\u0131k ortamlar\u0131nda uygulanabilirli\u011fin ve s\u00fcrd\u00fcr\u00fclebilir ba\u015far\u0131n\u0131n \u00f6rne\u011fi olabilir.<\/p>\n
Sonu\u00e7 olarak, CHANCES denemesi kanser \u00f6nleme biliminde \u00f6nemli bir ad\u0131m olarak g\u00f6r\u00fclebilir. Hem klinik y\u00f6ntemlerde hem de halk sa\u011fl\u0131\u011f\u0131 stratejilerinde kapsaml\u0131 ve entegre bir yakla\u015f\u0131m sunuyor. \u00c7in s\u0131n\u0131rlar\u0131n\u0131 a\u015fan etkisiyle, d\u00fcnya geneline yay\u0131lan benzer \u00e7al\u0131\u015fmalara ilham verebilir ve kaynak k\u0131s\u0131tl\u0131 b\u00f6lgelerde kanser taramas\u0131n\u0131n yeni standartlar\u0131n\u0131 belirleyebilir. Erken te\u015fhiste yeni bir d\u00f6nemin habercisi olarak g\u00f6sterilmektedir.<\/p>\n
—<\/p>\n
Ara\u015ft\u0131rma Konusu<\/strong>: \u00c7in n\u00fcfusunda akci\u011fer ve kolorektal kanser tarama stratejilerinin randomize kontroll\u00fc \u00e7al\u0131\u015fma ile kar\u015f\u0131la\u015ft\u0131r\u0131lmas\u0131.<\/p>\n Makale Ba\u015fl\u0131\u011f\u0131<\/strong>: A study protocol for the CHinA National CancEr screening (CHANCES) trial: a randomized controlled study to compare the screening strategies for lung cancer and colorectal cancer.<\/p>\n Web References<\/strong>: https:\/\/doi.org\/10.1186\/s12885-025-14152-6<\/p>\n Doi Referans<\/strong>: https:\/\/doi.org\/10.1186\/s12885-025-14152-6<\/p>\n Resim Credits<\/strong>: Scienmag.com<\/p>\n Anahtar Kelimeler<\/strong>: kanser tarama protokolleri, CHANCES denemesi metodolojisi, kolorektal kanser tespit y\u00f6ntemleri, geli\u015fmekte olan b\u00f6lgelerde erken kanser te\u015fhisi, geni\u015f \u00e7apl\u0131 sa\u011fl\u0131k ara\u015ft\u0131rmalar\u0131, d\u00fc\u015f\u00fck dozlu bilgisayarl\u0131 tomografi etkinli\u011fi, akci\u011fer kanseri tarama stratejileri, akci\u011fer kanserinde mortalite azalmas\u0131, n\u00fcfus temelli kanser verilerinin \u00f6nemi, kanser \u00fczerine randomize kontroll\u00fc \u00e7al\u0131\u015fma<\/p>\n","protected":false},"excerpt":{"rendered":" Geli\u015fmekte olan b\u00f6lgelerdeki kanser tarama protokollerini k\u00f6kten de\u011fi\u015ftirebilecek b\u00fcy\u00fck \u00f6l\u00e7ekli ve kapsaml\u0131 bir ara\u015ft\u0131rma olan CHinA National CancEr Screening (CHANCES) \u00e7al\u0131\u015fmas\u0131 ba\u015flad\u0131. Bu be\u015f y\u0131l s\u00fcrecek randomize kontroll\u00fc \u00e7al\u0131\u015fma, akci\u011fer ve kolorektal kanser tarama y\u00f6ntemlerini optimize etmeyi ama\u00e7layarak, erken te\u015fhisi g\u00fc\u00e7lendirecek ve geli\u015fmekte olan \u00fclkelerde hala y\u00fcksek seyreden kanser kaynakl\u0131 \u00f6l\u00fcmleri azaltmay\u0131 hedefliyor. Ara\u015ft\u0131rma, \u00c7in\u2019in…<\/p>\n","protected":false},"author":1,"featured_media":3019,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_yoast_wpseo_title":"","_yoast_wpseo_metadesc":"","_yoast_wpseo_focuskw":"","rank_math_title":"","rank_math_description":"","rank_math_focus_keyword":"","_wpan_schema_json_ld":"","_wpan_ai_seo_metadata":"","_wpan_ai_seo_status":"","_wpan_ai_seo_policy":"","_wpan_ai_seo_faq_block":"","_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[28],"tags":[1118,1120,1121,1117,1119],"tmauthors":[],"class_list":{"0":"post-3018","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-kanser","8":"tag-akciger-kanseri-tarama-yontemleri-ldct","9":"tag-cin-ulusal-kanser-tarama-calismasi","10":"tag-dusuk-ve-orta-gelirli-ulkelerde-kanser-tarama-stratejileri","11":"tag-kanser-tarama-protokolleri-gelismekte-olan-ulkeler","12":"tag-kolorektal-kanser-erken-teshis-ve-tarama"},"jetpack_featured_media_url":"https:\/\/haber360.com\/wp-content\/uploads\/2025\/04\/Akciger-ve-Kolorektal-Kanser-Tarama-Karsilastirmasi-1744917276.jpg","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/posts\/3018","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/comments?post=3018"}],"version-history":[{"count":0,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/posts\/3018\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/media\/3019"}],"wp:attachment":[{"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/media?parent=3018"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/categories?post=3018"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/tags?post=3018"},{"taxonomy":"tmauthors","embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/tmauthors?post=3018"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}